Statements (31)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
gptkb:drug |
| gptkbp:approvalYear |
2017
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
L01EM23
|
| gptkbp:brand |
gptkb:Aliqopa
|
| gptkbp:CASNumber |
1032754-93-6
|
| gptkbp:developedBy |
gptkb:Bayer
|
| gptkbp:hasMolecularFormula |
C23H28N8O4
|
| gptkbp:hasSMILES |
CC1=CC(=O)N(C2=NC=NC(N3CCN(CC3)CCO)=N2)C4=CC=CC=C14
|
| https://www.w3.org/2000/01/rdf-schema#label |
copanlisib
|
| gptkbp:indication |
relapsed follicular lymphoma after at least two prior therapies
|
| gptkbp:KEGGID |
gptkb:D10841
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
PI3K inhibitor
|
| gptkbp:molecularWeight |
480.52 g/mol
|
| gptkbp:PubChem_CID |
gptkb:CHEMBL2105728
gptkb:DB12023 25154815 |
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
diarrhea
hypertension leukopenia hyperglycemia pneumonitis |
| gptkbp:target |
gptkb:PI3K-delta
gptkb:PI3K-alpha |
| gptkbp:UNII |
8Y6I1W0A1I
|
| gptkbp:usedFor |
treatment of follicular lymphoma
|
| gptkbp:bfsParent |
gptkb:protein
|
| gptkbp:bfsLayer |
4
|